Phase I study of everolimus and mitomycin C for patients with metastatic esophagogastric adenocarcinoma

by Werner, Dominique, Atmaca, Akin, Pauligk, Claudia, Pustowka, Anette, Jäger, Elke, Al-Batran, Salah-Eddin
Published 2013

The prognostic impact of epidermal growth factor receptor in patients with metastatic gastric cancer

by Atmaca, Akin, Werner, Dominique, Pauligk, Claudia, Steinmetz, Kristina, Wirtz, Ralph, Altmannsberger, Hans-Michael, Jäger, Elke, Al-Batran, Salah-Eddin
Published 2012

The validation of a novel method combining both HER2 immunohistochemistry and HER2 dual-colour silver in situ hybridization on one slide for gastric carcinoma testing

by Werner, Dominique, Battmann, Achim, Steinmetz, Kristina, Jones, Tobin, Lamb, Tiffany, Martinez, Michele, Altmannsberger, Hans-Michael, Al-Batran, Salah-Eddin
Published 2014

SNAI2/SLUG and estrogen receptor mRNA expression are inversely correlated and prognostic of patient outcome in metastatic non-small cell lung cancer

by Atmaca, Akin, Wirtz, Ralph W, Werner, Dominique, Steinmetz, Kristina, Claas, Silke, Brueckl, Wolfgang M, Jäger, Elke, Al-Batran, Salah-Eddin
Published 2015

VEGFR-3 and CXCR4 as predictive markers for treatment with fluorouracil, leucovorin plus either oxaliplatin or cisplatin in patients with advanced esophagogastric cancer: a compara...

by Thomaidis, Thomas, Maderer, Annett, Al-Batran, Salah-Eddin, Kany, Janis, Pauligk, Claudia, Steinmetz, Kristina, Schad, Arno, Hofheinz, Ralf, Schmalenberg, Harald, Homann, Nils, Galle, Peter Robert, Moehler, Markus
Published 2014

Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas

by von Minckwitz, Gunter, Harder, Sebastian, Hövelmann, Sascha, Jäger, Elke, Al-Batran, Salah-Eddin, Loibl, Sibylle, Atmaca, Akin, Cimpoiasu, Christian, Neumann, Antje, Abera, Aklil, Knuth, Alexander, Kaufmann, Manfred, Jäger, Dirk, Maurer, Alexander B, Wels, Winfried S
Published 2005

Correction: Phase I clinical study of the recombinant antibody-toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas

by von Minckwitz, Gunter, Harder, Sebastian, Hövelmann, Sascha, Jäger, Elke, Al-Batran, Salah-Eddin, Loibl, Sibylle, Atmaca, Akin, Cimpoiasu, Christian, Neumann, Antje, Abera, Aklil, Knuth, Alexander, Kaufmann, Manfred, Jäger, Dirk, Maurer, Alexander B, Wels, Winfried S
Published 2006

Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO...

by Moehler, Markus, Gepfner-Tuma, Irina, Maderer, Annett, Thuss-Patience, Peter C., Ruessel, Joern, Hegewisch-Becker, Susanna, Wilke, Hansjochen, Al-Batran, Salah-Eddin, Rafiyan, Mohammad-Reza, Weißinger, Florian, Schmoll, Hans-Joachim, Kullmann, Frank, von Weikersthal, Ludwig Fischer, Siveke, Jens T., Weusmann, Jens, Kanzler, Stephan, Schimanski, Carl Christoph, Otte, Melanie, Schollenberger, Lukas, Koenig, Jochem, Galle, Peter R.
Published 2016

Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib

by Joensuu, Heikki, Eriksson, Mikael, Hall, Kirsten Sundby, Hartmann, Jörg T, Pink, Daniel, Schütte, Jochen, Ramadori, Giuliano, Hohenberger, Peter, Duyster, Justus, Al-Batran, Salah-Eddin, Schlemmer, Marcus, Bauer, Sebastian, Wardelmann, Eva, Sarlomo-Rikala, Maarit, Nilsson, Bengt, Sihto, Harri, Ballman, Karla V, Leinonen, Mika, DeMatteo, Ronald P, Reichardt, Peter
Published 2014